Teva’s products portfolio in the CNS field include Copaxone for the treatment of relapsing forms of multiple sclerosis, Ajovy for the preventive treatment of migraine in adults and Austedo for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia.
In the respiratory therapeutic area, products include ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, Braltus, Cinqair/Cinqaero, DuoResp Spiromax and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease.
Oncology therapeutic offerings consist of Bendeka, Treanda, Granix, Trisenox, Lonquex and Tevagrastim/Ratiograstim.
Teva has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products and a risperidone suspension for the treatment of patients with schizophrenia.
Teva Pharmaceutical Industries stock has a $14 target price at Barclays. The consensus target is $9.72, and the shares last traded at $7.45 on Friday.
The sports apparel stock has been crushed but looks like a solid bargain. Under Armour Inc. (NYSE: UAA) engages in the developing, marketing and distributing performance apparel, footwear and accessories for men, women and youth. The company offers its apparel in compression, fitted and loose-fit types.
The company also provides footwear products for running, training, basketball, cleated sports, recovery and outdoor applications. The company’s accessories include gloves, bags, headwear and sports masks, and it offers digital subscription and advertising services under the MapMyRun and MapMyRide platforms.
Under Armor primarily offers its products under the Under Armor, UA, HeatGear, ColdGear, HOVR, Protect This House, I Will, UA Logo, Armour Fleece and Armour Bra brands. The company sells its products through wholesale channels, including national and regional sporting goods chains, independent and specialty retailers, department store chains, mono-branded Under Armour retail stores, institutional athletic departments, and leagues and teams, as well as independent distributors and directly to consumers through a network of 422 brand and factory house stores, as well as through e-commerce.
The $15 UBS target price is well below the $26.20 consensus figure, but Under Armour stock closed at $7.11 on Friday.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.